(6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one
• 化学式: C₁₅H₂₀O₂
• 分子量: 232.32
• InChiKey: HRYLQFBHBWLLLL-XOUVJIAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pharmaceutical Composition Containing as Active Ingredient Extract From Bark of Liriodendron Tulipifera
  申请人：CHO DANG PHARM CO., LTD.

  公开号：US20150011623A1

  公开（公告）日：2015-01-08

  The present invention relates to a pharmaceutical composition containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera. More specifically, the present invention relates to a pharmaceutical composition for treating the gastrointestinal tract, the composition containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera, and to the use thereof as a therapeutic agent for gastrointestinal diseases.
• Method for extracting treatment ingredients for gastrointestinal diseases from bark of liriodendron tulipifera
  申请人：CHO DANG PHARM. CO., LTD.

  公开号：US20150011624A1

  公开（公告）日：2015-01-08

  The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of Liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.
• METHOD FOR SEPARATING THERAPEUTIC AGENT FOR CHRONIC MYELOGENOUS LEUKEMIA FROM BARK OF LIRIODENDRON TULIPIFERA L.
  申请人：CHO DANG PHARM. CO., LTD.

  公开号：US20160081979A1

  公开（公告）日：2016-03-24

  The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of Liriodendron tulipifera L., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a C1-C3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-tulipinolide and costunolide.
• US9283205B2
  申请人：——

  公开号：US9283205B2

  公开（公告）日：2016-03-15